Author(s)

Nishant Patnaik

www.neurophysiologyblog.com, Varanasi, India.

Alzheimer’s disease (AD) is progressively being recognized amongst the most vital medical and social issues in older individuals in industrialized and non-industrialized countries. To date, just symptomatic medications exist for this disease, all attempting to offset the neurotransmitter disturbance. Recently, cholinesterase inhibitors (CIs) are now accessible and have been authorized for the treatment of mild to moderate AD. Further remedial alternative available for moderate to severe AD is memantine, an N-methyl-D-aspartate receptor noncompetitive antagonist. Treatments equipped for halting or slightly adjusting the course of AD are known as “ailment changing” medications, and are still under extensive examination. To obstruct the movement of the ailment, they need to interfere with the pathogenic steps in charge of the clinical symptoms, including the disposition of extracellular amyloid β plaques and intracellular neurofibrillary tangle formation, irritation, oxidative damage, iron deregulation and cholesterol metabolism. This paper discusses the cure for Alzheimer’s disease, the current symptomatic treatments and the treatment of mild and moderate Alzheimer’s disease and the functions of its drugs.

Alzheimer’s Disease, Cure for Alzheimer’s Disease, Treatment Drugs, Acetylcholine, Inhibitors

Patnaik, N. (2015) Cure for Alzheimer’s Disease. World Journal of Neuroscience, 5, 328-330. doi: 10.4236/wjns.2015.55030.